Command Palette

Search for a command to run...

Preprint WatchModerateOctober 18th, 2026

Dual blockade of IL-18 and IL-4R alpha by a bispecific antibody for improved treatment of atopic dermatitis

Zhang, L.; Meng, Z.; Bo, H.; Tian, Y.; Mou, W.; Ping, X.; Dong, J.; Li, Y. L.

Concurrent IL-18 neutralisation and IL-4R alpha blockade by a single bispecific antibody suppresses type 1, type 2 and type 3 inflammation in atopic dermatitis more completely than either target alone, and removes the paradoxical IL-22 rise associated with selective IL-4R alpha blockade.

Moderate contradiction

1 prior failure

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

FJ0125 pairs an IL-18 binding protein with an anti-IL-4R alpha antibody and reports broader suppression of type 1, type 2 and type 3 cytokines than either component alone, in human ILC2 and Th2 assays and in an MC903 plus Staphylococcus aureus dermatitis model. The Claidex graph already records an efficacy failure against this target in this disease: GSK1070806, an anti-IL-18 antibody, failed on efficacy in a Phase 2b trial in moderate-to-severe atopic dermatitis (gsk1070806-il18-atopic-dermatitis-phase2b-efficacy-futility). The preprint does not directly contradict that result, because it argues IL-18 neutralisation is useful only alongside IL-4R alpha blockade, and it reports that FJ0125 abrogated the paradoxical IL-22 rise seen with selective IL-4R alpha blockade. The open risk is that the IL-18 half of this bispecific targets a mechanism that has already failed as monotherapy in this exact indication, so the incremental benefit over IL-4R alpha blockade alone remains untested in patients. Preclinical potency against a mixed cytokine signature is weaker evidence than a controlled comparison against dupilumab, which is the comparator any clinical programme will face.

Abstract excerpt

Atopic dermatitis is a chronic inflammatory dermatosis primarily driven by type 2 immunity, with type 1 and type 3 components that may limit the benefit of IL-4R alpha blockade alone. IL-18, an epithelial alarmin genetically associated with atopic dermatitis and correlated with disease severity, has been implicated as an upstream amplifier. The authors generated FJ0125, a bispecific antibody comprising human IL-18 binding protein fused to a humanised anti-IL-4R alpha antibody, and characterised binding, signalling and functional activity in vitro and in vivo. FJ0125 bound IL-18 and IL-4R alpha with high affinity, inhibited IL-4 and IL-13 signalling with dupilumab-comparable potency, and neutralised human and mouse IL-18. In vitro it suppressed IL-18 driven lymphocyte activation and type 1, type 2 and type 3 cytokine production more effectively than IL-18BP-Fc or IL-4R alpha monotherapy. In vivo it reduced multitype cytokines, improved dermatitis, lowered serum IgE, and abrogated the paradoxical IL-22 increase seen with selective IL-4R alpha blockade. Preprint, bioRxiv immunology, posted 17 October 2026, not peer reviewed.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.